Kyntra Bio Inc (NASDAQ:KYNB) Stock Now Rated “Hold” by Sell-Side Brokerages

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have been assigned an average rating of “Hold” from the seven brokerages that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $36.80.

KYNB has been the topic of several recent analyst reports. Zacks Research downgraded Kyntra Bio from a “hold” rating to a “strong sell” rating in a research report on Monday, October 12th. HC Wainwright reissued a “buy” rating and issued a $43.00 price target on shares of Kyntra Bio in a research note on Tuesday, September 1st. Maxim Group started coverage on Kyntra Bio in a report on Tuesday, October 13th. They issued a “buy” rating and a $35.00 price target for the company. Oppenheimer assumed coverage on Kyntra Bio in a report on Monday, July 6th. They issued an “outperform” rating and a $35.00 price target for the company. Finally, Weiss Ratings downgraded shares of Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 9th.

Institutional Investors Weigh In On Kyntra Bio

An institutional investor recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC bought a new position in Kyntra Bio Inc (NASDAQ:KYNB) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 72.71% of the company’s stock.

Kyntra Bio Price Performance

Shares of NASDAQ:KYNB opened at $5.28 on Wednesday. Kyntra Bio has a 52 week low of $4.85 and a 52 week high of $11.65. The business has a fifty day simple moving average of $7.08 and a 200-day simple moving average of $7.07.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.